

Treatment of ADHD Using High and Low Frequency Paired Associative Deep Transcranial Magnetic Stimulation

NCT07105475

Status	RECRUITING
Phase	Not Applicable
Sponsor	Ben-Gurion University of the Negev
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (4)

- Men and women aged 21-65.
- Aligned with the diagnosis of ADHD according to the criteria of the DSM-5.
- Participants taking medication for the treatment of attention deficit hyperactivity disorder will be asked, starting one week before the start of the treatment until the end, to take Ritalin IR 10mg (provided that the taking of the medication will be done at least 8 hours before the start of the treatment or at least one hour after it. This instruction is also valid for taking the medication on the days of the follow-up sessions (4 and 8 weeks from the end of the daily treatment phase). Ritalin is given as the only option because a drug with a short half-life is needed. The dose can be increased up to 20 mg per dose). The choice of this drug is to ensure that changes in brain function/activity are not the result of the Ritalin medication but of the research intervention.
- Give their written and oral consent to participate in the study.

Exclusion (16)

- Additional active psychiatric disorders in Axis I of the DSM-5.
- Antipsychotic treatment, antidepressants, or mood stabilizers.
- History of intolerance to TMS.
- Diagnosis of severe personality disorder according to the DSM-5.
- Current suicidal tendency.

... and 11 more (see full listing online)

Locations (1 total)

Ben Gurion University of the Negev, Beersheba, Israel